Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Zero Fee Index Funds Comparison lays out key metrics to compare funds with zero-fee structures, aiding you in selecting the most economical option.
14,041 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
When big-name releases head to vinyl, your wallet feels the impact. This guide breaks down budgeting, costs, and prac...
Single residents aim to live in Manhattan without roommates, but success hinges on an investment plan that covers hig...
SpaceX shares have tumbled from their peak, trading around $125 as of mid-July 2026. Analysts debate whether the retr...
A surge in retirees buying larger homes in 2026 is colliding with a silent Medicare premium hike. Large IRA withdrawa...
A legendary survival story becomes a blueprint for smart investing. Learn practical, numbers-driven steps to weather ...
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
A looming funding gap in Social Security invites tough questions for your retirement. This guide explains what insolv...
Jamie Dimon's latest warning is fueling questions about risk, debt, and AI-driven momentum. This analysis breaks down...
AT&T stunned investors with a record quarter, accelerating buybacks and signaling a robust cash flow backdrop. Here’s...
Adding someone to your home deed isn't a small favor—it's a major legal move. Here are five key considerations and sa...
Founders Fund has fully exited ETHZilla, and Peter Thiel has followed with a complete stake unload, underscoring a br...